OncoMatch/Clinical Trials/NCT07295951
A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia
Is NCT07295951 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including 14C-bleximenib and bleximenib for acute lymphoblastic leukemia.
Treatment: 14C-bleximenib · bleximenib — The purpose of this study is to assess how the body absorbs, breaks down (metabolism), and removes (excretes) radiolabeled bleximenib (a drug molecule that has been chemically bonded with a radioactive isotope which emits radiation making it easier to track in the body) in participants with acute leukemia (highly aggressive blood cancer typically characterized by large numbers of immature white blood cells in the bone marrow).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Biomarker criteria
Required: KMT2A (MLL) gene alteration
Required: NPM1 gene alteration
Required: NUP214 gene alteration
Required: NUP98 gene alteration
Performance status
ECOG 0–1(Restricted strenuous activity)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07295951 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require KMT2A?
Yes, KMT2A gene alteration is a required biomarker for enrollment.
Does this trial require NPM1?
Yes, NPM1 gene alteration is a required biomarker for enrollment.
Does this trial require NUP214?
Yes, NUP214 gene alteration is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify